Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
نویسندگان
چکیده
منابع مشابه
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to d...
متن کاملFibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family. Acting in an endocrine fashion, it increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence shows a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis...
متن کاملFibroblast Growth Factor 21: A Novel Metabolic Regulator
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic ...
متن کاملBetaKlotho is required for metabolic activity of fibroblast growth factor 21.
Fibroblast growth factor 21 (FGF21) is a liver-derived endocrine factor that stimulates glucose uptake in adipocytes. Here, we show that FGF21 activity depends on betaKlotho, a single-pass transmembrane protein whose expression is induced during differentiation from preadipocytes to adipocytes. BetaKlotho physically interacts with FGF receptors 1c and 4, thereby increasing the ability of these ...
متن کاملFibroblast growth factor 21, a biomarker for mitochondrial muscle disease.
For many patients, a mitochondrial disease diagnosis is often difficult to establish with certainty, except in cases with a classical clinical presentation. Invasive and time-consuming methods, such as tissue biopsy and enzymatic studies, are frequently necessary before proceeding to molecular genetic analyses, because of the low specificity and sensitivity of existing lessinvasive biomarkers, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Endocrinology
سال: 2015
ISSN: 1664-2392
DOI: 10.3389/fendo.2015.00168